Generic Drug News and Research

RSS

Generic Drugs are official nonbrand names by which medicines are known. Generic names usually refer to the chemical name of the drug.

Teva asserts infringement of 4 COPAXONE-related patents by Mylan, files complaint in U.S. District Court

Teva Pharmaceutical Industries Ltd. announced today it has filed a complaint in the U.S. District Court for the Southern District of New York against Mylan asserting infringement of four patents related to the characterization of COPAXONE® (glatiramer acetate injection). The latest of these patents expires in February 2020.

22 Sep 2010

Multinational study demonstrates positive effects of laquinimod in patients with RRMS

Teva Pharmaceutical Industries Ltd. and Active Biotech today announced results from a 36-week active extension study evaluating two doses of laquinimod, an investigational, once-daily oral immunomodulator, for the treatment of relapsing remitting multiple sclerosis.

21 Sep 2010

Opiate usage increases in workplace and ER

More American workers and job applicants are testing positive for prescription opiates, according to U.S. general workforce data in the 2009 annual Drug Testing Index™ (DTI) released today by Quest Diagnostics Incorporated, the nation's leading provider of diagnostic testing, information and services. Results from more than 5.5 million urine drug tests reveal an 18 percent jump in opiate positives in the general U.S. workforce in a single year (2008 to 2009), and a more than 40 percent climb from 2005 to 2009.

17 Sep 2010

Elite Pharmaceuticals signs agreements with Precision Dose for four generic products

Elite Pharmaceuticals, Inc. announced today the signing of a license agreement and a manufacturing and supply agreement with Precision Dose, Inc. which has a wholly owned subsidiary, TAGI Pharma, Inc. which will distribute the products covered by the agreement. Pursuant to the License Agreement, TAGI Pharma will market and sell four Elite generic products in the United States, Puerto Rico and Canada.

17 Sep 2010

AMCP supports legislation to prohibit financial agreements for delaying marketing of lower-cost generic drugs

The Academy of Managed Care Pharmacy (AMCP) supports the inclusion of legislative language similar to S. 369 — the Preserve Access to Affordable Generics Act — in appropriations legislation now under consideration by the Senate. S. 369 would prohibit financial agreements between brand-name and generic pharmaceutical manufacturers to delay the marketing of lower-cost generic drugs.

14 Sep 2010

Walgreens August sales increase 8.6% to $5.66 billion

Walgreens had August sales of $5.66 billion, an increase of 8.6 percent from $5.22 billion for the same month in 2009. Duane Reade stores, acquired in April 2010, contributed 2.8 percentage points to the total sales increase for the month.

3 Sep 2010

Study determines dose-specific patterns associated with generic statin switching

Research conducted in the Netherlands has highlighted the need for care when switching patients under treatment for high cholesterol from branded to generic drug families. The study shows that much of the switching can result in patients inadvertently receiving non-equivalent doses, potentially leading to an increased risk of downstream heart disease and stroke.

31 Aug 2010

Ralphs Grocery Company to offer seasonal flu vaccine at $25

Ralphs Grocery Company is making it easy and affordable for customers to stay healthy by getting seasonal flu immunizations early.

31 Aug 2010

Ipsen 2010 first half revenue increases to €31.7 million

The Board of Directors of Ipsen, chaired by Jean-Luc Bélingard, met on August 30, 2010 to review the Group's results for the first half 2010, published today

31 Aug 2010

Humana and Availity deploy CarePrescribe to Kentucky Physicians at no charge

Humana Inc. and Availity, LLC today announced the deployment of CarePrescribe, an electronic prescribing service, at no charge to eligible physician practices in Kentucky. Following the successful introduction of Availity CarePrescribe in Florida and Texas - where approximately 2,000 physicians are using the system - Kentucky physicians now have access to the free service as a valuable tool in improving efficiency, safety and quality, while reducing patient costs.

24 Aug 2010

Jiangbo receives Shandong FDA approval to market Felodipine SR tablets

Jiangbo Pharmaceuticals, Inc., today announced that the Company received approval from the Shandong Food and Drug Administration to start the sales of Felodipine sustained release tablets.

16 Aug 2010

U.S. FDA purchases more licenses to Simulations Plus' DDDPlus software

Simulations Plus, Inc., a leading provider of software for pharmaceutical discovery and development, today announced that it has received a purchase order from the U.S. Food and Drug Administration to expand the number of licenses for the Company's DDDPlus™ simulation software.

13 Aug 2010

Graymark Healthcare second-quarter consolidated net revenues increase 12% to $28.3 million

Graymark Healthcare, Inc. today announced financial results for the quarter ending June 30, 2010 including $1.1MM of EBITDA on $28.3MM in sales.

10 Aug 2010

Teva completes ratiopharm acquisition

Teva Pharmaceutical Industries Ltd. announced today that it has completed the acquisition of ratiopharm, Germany's second largest generics producer. Following the acquisition, Teva will be the number one generic company in Europe, holding the leading market position in ten countries, as well as ranking in the top three in seven additional countries. In addition, the transaction will significantly increase Teva's sales in Canada.

10 Aug 2010

TEMPO study recommends early administration of Azilect in PD patients

Teva Pharmaceutical Industries Ltd. and H. Lundbeck A/S (Lundbeck) today announced newly published long-term data on Azilect(rasagiline tablets) from the TEMPO study and its open-label extension. The findings confirm the long-term efficacy, safety and tolerability of Azilect® in patients with Parkinson's disease (PD) and further demonstrate the benefits obtained with early treatment initiation. The data was published in the June 2010 issue of the International Journal of Neuroscience.

6 Aug 2010

Par Pharmaceutical second-quarter total net revenues decrease 37% to $255.5 million

Par Pharmaceutical Companies, Inc. today reported results for the second quarter ended June 30, 2010.

4 Aug 2010

IPS looks at anticipated impact of free-trade talks on India's generic drug industry

With reports that ongoing negotiations between India and the European Union are expected to end in a free-trade agreement "by the end of August," Inter Press Service examines the concerns among drug manufacturers and exporters over how the agreement might reduce growth in India's generic medicines industry.

4 Aug 2010

European Commission grants Teva approval for acquisition of ratiopharm

Teva Pharmaceutical Industries Ltd. announced today that the Company received approval from the European Commission to proceed with its acquisition of ratiopharm.

4 Aug 2010

Senate panel votes to end drug industry's practice of 'pay-to-delay' generics

The Associated Press: "In a defeat for the powerful drug lobby, a Senate panel approved legislation to prohibit drug companies from paying generic drug makers to delay bringing less costly products to market. … The measure would ban a 'pay-to-delay' practice — opposed by the [Federal Trade Commission] in a series of lawsuits brought since 2001 — in which brand-name drug companies and generic drug makers both profit. Brand-name drug makers get higher prices while the generic companies are paid to stay out of the market."

31 Jul 2010

McKesson first-quarter revenues increase to $27.5 billion

McKesson Corporation today reported that revenues for the first quarter ended June 30, 2010 were $27.5 billion compared to $26.7 billion a year ago. First-quarter earnings per diluted share was $1.10 compared to $1.06 per diluted share a year ago.

30 Jul 2010

Generic Drug News and Research

Further Reading

Teva asserts infringement of 4 COPAXONE-related patents by Mylan, files complaint in U.S. District Court

Multinational study demonstrates positive effects of laquinimod in patients with RRMS

Opiate usage increases in workplace and ER

Elite Pharmaceuticals signs agreements with Precision Dose for four generic products

AMCP supports legislation to prohibit financial agreements for delaying marketing of lower-cost generic drugs

Walgreens August sales increase 8.6% to $5.66 billion

Study determines dose-specific patterns associated with generic statin switching

Ralphs Grocery Company to offer seasonal flu vaccine at $25

Ipsen 2010 first half revenue increases to €31.7 million

Humana and Availity deploy CarePrescribe to Kentucky Physicians at no charge

Jiangbo receives Shandong FDA approval to market Felodipine SR tablets

U.S. FDA purchases more licenses to Simulations Plus' DDDPlus software

Graymark Healthcare second-quarter consolidated net revenues increase 12% to $28.3 million

Teva completes ratiopharm acquisition

TEMPO study recommends early administration of Azilect in PD patients

Par Pharmaceutical second-quarter total net revenues decrease 37% to $255.5 million

IPS looks at anticipated impact of free-trade talks on India's generic drug industry

European Commission grants Teva approval for acquisition of ratiopharm

Senate panel votes to end drug industry's practice of 'pay-to-delay' generics

McKesson first-quarter revenues increase to $27.5 billion

A New Approach to Preventing Bladder Cancer Recurrence

Bringing real-time analytics to downstream bioprocess monitoring

Designing fluidic architecture for scalable diagnostic platforms

Latest News